ET
CCCC icon

Entropy Technologies’s C4 Therapeutics CCCC Stock Holding History

Entropy Technologies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,391
Closed -$126K – 699
2024
Q1 		$126K Buy
+15,391
New +$119K 0.01% 681

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Entropy Technologies's CCCC Position: Q2 2024 in Review

Entropy Technologies sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 15,391 shares — an estimated $126K sold.

Entropy Technologies first reported a position in CCCC in Q1 2024 and held it in 1 quarter. The position peaked at $126K in Q1 2024. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

  • Entropy Technologies reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Entropy Technologies sold 15,391 C4 Therapeutics shares in Q2 2024, an estimated $126K.
  • Entropy Technologies first reported a position in C4 Therapeutics in Q1 2024 and held it in 1 quarter.
  • Entropy Technologies's C4 Therapeutics position peaked at $126K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Entropy Technologies's 13F filing for Q2 2024, filed 12 Aug 2024.